Short answer
Crinetics Pharmaceuticals, Inc. (CRNX) filed an 8-K current report with the SEC on September 1, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 3.01 (Notice of Delisting), Item 3.03 (Material Modification to Rights of Security Holders), Item 5.01 (Changes in Control of Registrant), Item 5.02 (Departure/Election of Directors or Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws). Merger completion triggered termination of Crinetics’ employee stock purchase plan.
- This filing includes Item 3.01, an item that often signal trouble.
Crinetics Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.02 · Termination of a Material Definitive Agreement
- Merger completion triggered termination of Crinetics’ employee stock purchase plan
- Equity incentive plans from 2015, 2018, and 2021 terminated at the merger effective time
- $0.?? Sales Agreement with SVB Leerink and Cantor Fitzgerald ended, removing the equity issuance facility
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Item 2.01 references the Introductory Note for acquisition or disposition details
- Investors should review the Introductory Note to identify the transaction, consideration, assets, and expected financial impact
Item 3.01 · Notice of Delisting
- CRNX common stock trading suspended before market open on merger closing date
- Nasdaq delisting and SEC Form 25 deregistration requested following merger completion
- Form 15 expected to terminate registration and suspend SEC reporting obligations
- Public-market liquidity and periodic disclosures expected to end for CRNX shareholders
Item 3.03 · Material Modification to Rights of Security Holders
- Merger converted each outstanding Company common share into the right to receive merger consideration
- Former stockholders lost voting and other equity-holder rights at the merger’s effective time
- Shareholder entitlement now limited to receiving merger consideration under the merger agreement
Item 5.01 · Changes in Control of Registrant
- Merger completed, transferring control of Crinetics to Parent
- Crinetics became Parent’s wholly owned subsidiary, eliminating standalone public-company ownership
- Aggregate merger consideration approximately $10.0 billion
- Funding combined Parent cash on hand and term-loan borrowings
- No known arrangements for a subsequent change in control
Item 5.02 · Departure/Election of Directors or Officers
- Merger completion removed all seven incumbent directors from CRNX’s board and committees
- Resignations unrelated to disagreements over operations, policies, or practices
- Charles Wagner became sole director of the surviving corporation
- Post-merger leadership: Wagner President, Prasanna Thombre Treasurer, Omar White Secretary
- All pre-merger officers removed, signaling complete management transition
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Certificate of incorporation and bylaws fully amended and restated effective at merger closing
- Changes implemented under the Merger Agreement, signaling completed transaction mechanics
- Revised governing documents in Exhibits 3.1 and 3.2 define post-merger corporate governance terms
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Crinetics Pharmaceuticals, Inc. 8-K filings
Get the next CRNX 8-K as it lands
Follow CRNX for push alerts, or ask the research agent what this filing means.